nivolumab
E824658
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
Statements (57)
| Predicate | Object |
|---|---|
| instanceOf |
antineoplastic agent
ⓘ
human IgG4 monoclonal antibody ⓘ monoclonal antibody ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| ATCCode | L01FF03 ⓘ |
| bindingSite | extracellular domain of PD-1 receptor ⓘ |
| combinationIndication |
intermediate or poor-risk advanced renal cell carcinoma
ⓘ
malignant pleural mesothelioma ⓘ microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer ⓘ unresectable or metastatic melanoma ⓘ |
| combinationWith | ipilimumab NERFINISHED ⓘ |
| commonAdverseEffect |
diarrhea
ⓘ
fatigue ⓘ nausea ⓘ pruritus ⓘ rash ⓘ |
| contraindication | severe hypersensitivity to nivolumab or its excipients ⓘ |
| developedBy | Bristol Myers Squibb NERFINISHED ⓘ |
| dosingRegimen | weight-based or fixed-dose intravenous infusion every 2 to 4 weeks ⓘ |
| effectOnImmuneSystem |
increases cytokine production and T-cell proliferation
ⓘ
inhibits PD-1 mediated negative regulation of T-cell activation ⓘ |
| eliminationHalfLife | approximately 25 days ⓘ |
| firstApprovalCountry | Japan GENERATED ⓘ |
| firstApprovalYear | 2014 ⓘ |
| hasTradeName | Opdivo NERFINISHED ⓘ |
| immuneRelatedAdverseEffect |
colitis
ⓘ
hepatitis ⓘ hyperthyroidism ⓘ hypophysitis ⓘ hypothyroidism ⓘ nephritis ⓘ pneumonitis ⓘ skin reactions ⓘ |
| immunoglobulinSubclass | IgG4 kappa ⓘ |
| indication |
adjuvant treatment of melanoma
ⓘ
adjuvant treatment of non-small cell lung cancer ⓘ advanced renal cell carcinoma ⓘ classical Hodgkin lymphoma ⓘ colorectal cancer with microsatellite instability-high or mismatch repair deficiency ⓘ esophageal squamous cell carcinoma ⓘ gastric or gastroesophageal junction cancer ⓘ hepatocellular carcinoma ⓘ malignant pleural mesothelioma ⓘ metastatic non-small cell lung cancer ⓘ recurrent or metastatic squamous cell carcinoma of the head and neck ⓘ unresectable or metastatic melanoma ⓘ urothelial carcinoma ⓘ |
| legalStatus | prescription only ⓘ |
| mechanismOfAction |
blocks interaction between PD-1 and its ligands PD-L1 and PD-L2
ⓘ
enhances T-cell mediated anti-tumor immune response ⓘ |
| molecularType | recombinant human monoclonal antibody ⓘ |
| pregnancyCategory | can cause fetal harm based on mechanism of action ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets |
PD-1
NERFINISHED
ⓘ
programmed cell death protein 1 NERFINISHED ⓘ |
| usedInTherapy | cancer immunotherapy ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.